The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,870.00
Bid: 1,872.00
Ask: 1,886.00
Change: -16.00 (-0.85%)
Spread: 14.00 (0.748%)
Open: 1,814.00
High: 1,878.00
Low: 1,814.00
Prev. Close: 1,886.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition and strategic partnership

23 Feb 2017 07:00

RNS Number : 6110X
Genus PLC
23 February 2017
 

 

 

 

For immediate release 23 February 2017

Genus plc

('Genus' or the 'Group')

 

Acquisition and Strategic Partnership

Genus acquires Hermitage's genetic assets and enters into a strategic partnership

 

Genus, a leading global animal genetics company, and Hermitage, one of the longest established pig breeding companies in Europe, are pleased to announce that they have signed an agreement to enter into a strategic partnership covering the supply of porcine genetics in several markets.

 

PIC, Genus's porcine division, will acquire the genetic rights and intellectual property of Hermitage. Hermitage will also become a strategic supply chain and distribution partner for PIC. In addition, PIC will acquire certain Hermitage customer relationships in various geographies including Russia, the US and several European countries. The transaction is subject to a number of closing conditions which are expected to be fulfilled by the end of March 2017.

 

The partnership combines PIC's genetics expertise and quality, and Hermitage's supply chain network and operational excellence. This combination will strengthen PIC's ability to deliver genetic improvement in Europe and provide customers of both PIC and Hermitage with access to top-tier genetics and optimal technical and health services.

 

Hermitage was established in 1958 in Ireland and is one of the longest established porcine breeding and genetics companies in Europe. Over the years, Hermitage has grown into a multinational porcine breeding company serving pig producers in Europe and other international markets with high-health breeding stock. Hermitage's infrastructure includes nucleus farms and boar studs in Ireland and across Europe, as well as multiplication partners in key international territories.

 

Commenting on the transaction, Karim Bitar, Chief Executive of Genus, commented:

 

"The partnership with Hermitage is an ideal fit with our porcine strategy. It will provide Genus with the opportunity to accelerate genetic improvement by combining the PIC and Hermitage gene pools. In addition, Hermitage's strong supply chain and customer-service oriented team will strengthen our ability to serve pig producers efficiently and reliably."

 

Ned Nolan, owner of Hermitage, added:

 

"This is an exciting step for Hermitage, as we join forces with a global pioneer in our field. Our partnership with PIC will allow the continued use of the Hermitage gene pool to provide enhanced genetics to our global customer base. Hermitage shares PIC's values of pioneering genetic improvement for customers and we look forward to collaborating with PIC's team."

 

For further information, please contact:

 

Genus Tel: +44(0)1256 345970

Karim Bitar, Chief Executive

Stephen Wilson, Group Finance Director

Buchanan Tel: +44(0)207 466 5000

Charles Ryland /Vicky Hayns

 

This announcement is available on the Genus website www.genusplc.com

 

About Genus

Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across all livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

 

Genus's worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chain.

 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

 

With headquarters in Basingstoke, United Kingdom, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

 

About Hermitage

Hermitage was established in 1958 by the Nolan Family. Pedigree Landrace and Large White lines were purchased internationally and developed and selected with the support of Irish Government Central Test Stations in the 60s, 70s and 80s. Over the last 30 years Hermitage Genetics has expanded its Landrace, Large White, Duroc, Pietrain and Maxgro lines, becoming a pig breeding company dedicated to efficient and profitable pig production worldwide. Hermitage top class production facilities support customers across Europe, North America and Asia.

 

Hermitage has developed a science-based breeding program that drives genetic progress focused on traits that are of economic importance to the pig producer. Hermitage now tests over 30,000 pigs per year for lean efficient growth and collects data from more than 22,000 pure-bred sows at the genetic nucleus level. This data is analysed by Hermitage's proprietary BreedDirect BLUP software program and offered by Hermitage to customers through an online data portal. Hermitage Group was advised on the transaction by Investec Corporate Finance in Dublin.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQOKBDDDBKBABB
Date   Source Headline
1st Feb 20161:22 pmRNSBlocklisting Interim Review
4th Jan 20165:40 pmRNSTotal Voting Rights
11th Dec 20153:14 pmRNSDirector/PDMR Shareholding
9th Dec 20154:30 pmRNSDirector/PDMR Shareholding
8th Dec 20157:00 amRNSTackles major pig disease with breakthrough tech
1st Dec 20154:54 pmRNSHolding(s) in Company
1st Dec 20154:46 pmRNSTotal Voting Rights
19th Nov 20152:52 pmRNSResult of AGM
19th Nov 20157:00 amRNSAGM - TRADING UPDATE
2nd Nov 20153:04 pmRNSTotal Voting Rights
22nd Oct 20155:48 pmRNSHolding(s) in Company
21st Oct 20156:10 pmRNSDirector/PDMR Shareholding
15th Oct 201512:46 pmRNSAnnual Report and Notice of AGM
1st Oct 20153:00 pmRNSTotal Voting Rights
15th Sep 201511:00 amRNSDirector/PDMR Shareholding
8th Sep 20157:00 amRNSPreliminary Results
3rd Aug 20152:00 pmRNSBlocklisting Interim Review
30th Jun 20152:00 pmRNSTotal Voting Rights
29th Jun 20152:00 pmRNSChange of Registered Office
29th May 20152:00 pmRNSTotal Voting Rights
12th May 20157:00 amRNSCapital Markets Event and Trading Update
11th May 20152:00 pmRNSHolding(s) in Company
7th May 20152:21 pmRNSHolding(s) in Company
30th Apr 20152:00 pmRNSTotal Voting Rights
14th Apr 20152:00 pmRNSDirector/PDMR Shareholding
13th Apr 20155:06 pmRNSHolding(s) in Company
1st Apr 20157:00 amRNSCompletion of acquisition
31st Mar 20154:04 pmRNSTotal Voting Rights
19th Mar 20155:46 pmRNSDirector/PDMR Shareholding
12th Mar 20152:09 pmRNSDirector/PDMR Shareholding
9th Mar 20151:24 pmRNSDirector Declaration
27th Feb 20152:00 pmRNSTotal Voting Rights
24th Feb 201511:00 amRNSHolding(s) in Company
24th Feb 20157:00 amRNSInterim Results
16th Feb 20157:00 amRNSAcquisition of 51% of In Vitro Brasil
2nd Feb 20151:22 pmRNSBlock Listing Six Monthly Return
31st Dec 201412:01 pmRNSTotal Voting Rights
12th Dec 201410:44 amRNSDirector/PDMR Shareholding
1st Dec 20144:36 pmRNSTotal Voting Rights
21st Nov 20144:03 pmRNSDirector/PDMR Shareholding
14th Nov 20143:42 pmRNSResult of AGM
14th Nov 20147:00 amRNSTrading Update
31st Oct 201412:20 pmRNSTotal Voting Rights
22nd Oct 20149:29 amRNSDirector/PDMR Shareholding
10th Oct 20145:58 pmRNSHolding(s) in Company
8th Oct 20143:47 pmRNSAnnual Report and Annual General Meeting
3rd Sep 20147:00 amRNSPreliminary Results
3rd Sep 20147:00 amRNSPorcine Multiplication Agreement in China
29th Aug 20143:08 pmRNSTotal Voting Rights
1st Aug 20142:00 pmRNSBlock Listing 6 Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.